Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases

被引:10
|
作者
Okuno, M. [1 ]
Goumard, C. [1 ]
Mizuno, T. [1 ]
Kopetz, S. [2 ]
Omichi, K. [1 ]
Tzeng, C-W D. [1 ]
Chun, Y. S. [1 ]
Lee, J. E. [1 ]
Vauthey, J-N [1 ]
Conrad, C. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1400 Pressler,Unit 1484, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
FOLFIRI PLUS BEVACIZUMAB; LONG-TERM SURVIVAL; HEPATIC PEDICLE; INTRAHEPATIC CHOLANGIOCARCINOMA; 1ST-LINE TREATMENT; EXTRAHEPATIC DISEASE; MARGIN STATUS; RAS MUTATION; OPEN-LABEL; RESECTION;
D O I
10.1002/bjs.10822
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundAlthough perihepatic lymph node metastases (PLNMs) are known to be a poor prognosticator for patients with colorectal liver metastases (CRLMs), optimal management remains unclear. This study aimed to determine the risk factors for PLNMs, and the survival impact of their number and location in patients with resectable CRLMs. MethodsData on patients with CRLM who underwent hepatectomy during 2003-2014 were analysed retrospectively. Recurrence-free (RFS) and overall (OS) survival were calculated according to presence, number and location of PLNMs. Risk factors for PLNM were evaluated by logistic regression analysis. ResultsOf 1485 patients, 174 underwent lymphadenectomy, and 54 (310 per cent) had PLNM. Ten patients (57 per cent) who had lymphadenectomy and 176 (134 per cent) who did not underwent repeat hepatectomy. Survival of patients with PLNM was significantly poorer than that of patients without (RFS: 53 versus 138 months, P < 0001; OS: 205 versus 713 months; P < 0001). Median OS was significantly better in patients with para-aortic versus hepatoduodenal ligament PLNMs (582 versus 155 months; P = 0011). Patients with three or more PLNMs had significantly worse median OS than those with one or two (163 versus 254 months; P = 0039). The presence of primary tumour lymph node metastases (odds ratio 235; P = 0037) and intrahepatic recurrence requiring repeat hepatectomy (odds ratio 561; P = 0012) were significant risk factors for PLNM on multivariable analysis. ConclusionPatients undergoing repeat hepatectomy and those with primary tumour lymph node metastases are at significant risk of PLNM. Although PLNM is a poor prognostic factor independent of perihepatic lymph node station, patients with one or two PLNMs have a more favourable outcome than those with more PLNMs.
引用
下载
收藏
页码:1200 / 1209
页数:10
相关论文
共 50 条
  • [21] Staging of resectable colorectal liver metastases
    Scheele, J
    Stangl, R
    AltendorfHofmann, A
    SURGERY, 1996, 119 (01) : 118 - 119
  • [22] Sentinel lymph node mapping in liver resection for colorectal liver metastases
    Perini, Marcos V.
    Tai, James
    Muralidharan, Vijayaragavan
    Christophi, Christopher
    ANZ JOURNAL OF SURGERY, 2019, 89 (7-8) : 978 - 980
  • [23] Lymph Node Ratio and Liver Metachronous Metastases in Colorectal Cancer
    Li Destri, Giovanni
    Privitera, Giuseppe
    La Greca, Gaetano
    Scilletta, Roberto
    Pesce, Antonio
    Portale, Teresa Rosanna
    Conti, Erminia
    Puleo, Stefano
    INTERNATIONAL SURGERY, 2021, 105 (1-3) : 122 - 128
  • [24] Lymph node ratio and liver metachronous metastases in colorectal cancer
    Li Destri, Giovanni
    La Greca, Gaetano
    Pesce, Antonio
    Conti, Erminia
    Puleo, Stefano
    Portale, Teresa Rosanna
    Scilletta, Roberto
    Piazza, Martina
    ANNALI ITALIANI DI CHIRURGIA, 2019, 90 (04) : 275 - 280
  • [25] Molecular prognostic markers in resectable colorectal liver metastases: A systematic review
    Neal, C. P.
    Garcea, G.
    Doucas, H.
    Manson, M. M.
    Sutton, C. D.
    Dennison, A. R.
    Berry, D. P.
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (12) : 1728 - 1743
  • [26] Comment on "Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases''
    Watt, David G.
    Horgan, Paul G.
    McMillan, Donald C.
    MEDICAL ONCOLOGY, 2015, 32 (05)
  • [27] Comment on “Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases”
    David G. Watt
    Paul G. Horgan
    Donald C. McMillan
    Medical Oncology, 2015, 32
  • [28] The Role of Preoperative Chemotherapy in Patients with Resectable Colorectal Liver Metastases
    Benoist, Stephane
    Nordlinger, Bernard
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (09) : 2385 - 2390
  • [29] The Role of Preoperative Chemotherapy in Patients with Resectable Colorectal Liver Metastases
    Stéphane Benoist
    Bernard Nordlinger
    Annals of Surgical Oncology, 2009, 16 : 2385 - 2390
  • [30] Effect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases
    Zhu, Dexiang
    Zhong, Yunshi
    Wei, Ye
    Ye, Lechi
    Lin, Qi
    Ren, Li
    Ye, Qinghai
    Liu, Tianshu
    Xu, Jianmin
    Qin, Xinyu
    PLOS ONE, 2014, 9 (01):